Tricuspid regurgitation (TR) is frequently detected, especially in its secondary form, while primary TR is far less frequent. Similar to mitral regurgitation (MR), primary tricuspid regurgitation should require timely intervention to avoid secondary damage of the RV, which is associated with poor outcome. Current guidelines suggest that secondary TR should be treated at the time of left-sided valve surgery, although a surgical option is rarely offered to high-risk patients with combined heart valve disease. As such, while the transcatheter approach to mitral valve repair/replacement has become a major goal of the transcatheter therapies, the transcatheter tricuspid valve intervention is still at a very early stage. In this review, we provide an overview of the different stages of technical and clinical evolution of transcatheter treatment of patients with TR or MR, highlighting the challenges and the avenues for future research.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.carrev.2021.12.004 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Analysis of Calcium Patterns in the Thoracic Aorta and Clinical Outcomes of TAVR Patients Presenting with Porcelain Aorta.
J Clin Med
January 2025
Department of Cardiovascular Surgery, Institute Insure, German Heart Center Munich, School of Medicine & Health, Technical University of Munich, Lazarettstrasse 36, 80636 Munich, Germany.
: In the presence of porcelain aorta (PA), transcatheter aortic valve replacement (TAVR) has become a class I therapeutic indication for the treatment of severe aortic valve stenosis. To date, few studies have analyzed the clinical outcomes of TAVR in PA patients. We aim to analyze the calcification patterns of the thoracic aorta in PA patients and to evaluate their clinical implications for TAVR procedures.
View Article and Find Full Text PDFAll You Need to Know About TACE: A Comprehensive Review of Indications, Techniques, Efficacy, Limits, and Technical Advancement.
J Clin Med
January 2025
Department of Diagnostic and Interventional Radiology, Foundation IRCCS Cà Granda-Ospedale Maggiore Policlinico, Via Francesco Sforza 35, 20122 Milan, Italy.
Transcatheter arterial chemoembolization (TACE) is a proven and widely accepted treatment option for hepatocellular carcinoma and it is recommended as first-line non-curative therapy for BCLC B/intermediate HCC (preserved liver function, multifocal, no cancer-related symptoms) in patients without vascular involvement. Different types of TACE are available nowadays, including TAE, c-TACE, DEB-TACE, and DSM-TACE, but at present there is insufficient evidence to recommend one TACE technique over another and the choice is left to the operator. This review then aims to provide a comprehensive overview of the current literature on indications, types of procedures, safety, and efficacy of different TACE treatments.
View Article and Find Full Text PDFEvaluating the Impacts of Procedural and Patient-Specific Factors on the Outcomes of Transcatheter Aortic Valve Implantation (TAVI).
Medicina (Kaunas)
January 2025
Department of Cardiology, Hospital of Lithuanian University of Health Sciences Kauno Klinikos, Lithuanian University of Health Sciences, 2 Eivenių Str., LT-50009 Kaunas, Lithuania.
: Transcatheter aortic valve implantation (TAVI) has emerged as a pivotal intervention for managing severe aortic stenosis in high-risk surgical patients. : This study aimed to evaluate the impacts of procedural factors and patient characteristics on TAVI outcomes, with a focus on survival rates, cardiac mortality, and associated complications. : A retrospective, single-center study involving 224 patients who underwent TAVI at the Lithuanian University of Health Sciences from September 2021 to April 2023 was conducted.
View Article and Find Full Text PDFEfficacy of Adding Locoregional Therapy in ATZ/BEV-Treated Patients with Stable HCC.
Cancers (Basel)
January 2025
Department of Gastroenterology and Hepatology, Osaka Rosai Hospital, 1179-3 Nagasonecho, Kita Ward, Sakai 591-8025, Osaka, Japan.
: Combination therapy with atezolizumab and bevacizumab (ATZ/BEV) is extremely effective and yields a high response rate in patients with hepatocellular carcinoma (HCC). In this study, the efficacy of adding locoregional therapy to ATZ/BEV in patients with stable disease (SD) HCC was investigated. : One hundred five HCC patients who were treated with ATZ/BEV or lenvatinib (LEN) as first-line chemotherapy for unresectable HCC were evaluated on the basis of the modified RECIST criteria.
View Article and Find Full Text PDFEfficacy analysis of drug-eluting beads transcatheter arterial chemoembolization combining systemic chemotherapy and immune checkpoint inhibitors in unresectable intrahepatic cholangiocarcinoma: a multicenter retrospective cohort study based on propensity score matching.
World J Surg Oncol
January 2025
Dalian Medical University, No.9 Western Section, Lvshun South Street, Lvshun District, Dalian, 116044, Liaoning Province, China.
Objective: To investigate the efficacy and safety of drug-eluting beads transcatheter arterial chemoembolization(DEB-TACE) combined with systemic chemotherapy and immune checkpoint inhibitors in the treatment of unresectable intrahepatic cholangiocarcinoma.
Methods: This study used retrospective cohort analysis to collect the clinical data of 209 patients with unresectable intrahepatic cholangiocarcinoma treated in Linyi Cancer Hospital, Affiliated Zhongshan Hospital of Dalian University, Affiliated Central Hospital of Dalian University of Technology from January 2020 to January 2024. The patients were divided into observation group and control group based on their treatment plans.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!